Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.60 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | INSR | P06213 | 5/20 | 0.54 |
| ▸ | IGF1R | P08069 | 5/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.54 |
| ▸ | MET | P08581 | 2/20 | 0.51 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.49 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | STK25 | O00506 | 1/20 | 0.49 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | CASK | O14936 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | GAK | O14976 | 1/20 | 0.49 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.49 |
| ▸ | MUSK | O15146 | 1/20 | 0.49 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26778501 | 0.88 | EGFR (0.55) | EGFRBRD4INSRIGF1RALK | |
| SCHEMBL24328525 | 0.86 | EGFR (0.58) | EGFRBRD4JAK2ABL1CDK4 | |
| SCHEMBL26906554 | 0.86 | EGFR (0.68) | EGFRBRD4INSRIGF1RALK | |
| SCHEMBL26778497 | 0.86 | EGFR (0.59) | EGFRBRD4JAK2ABL1CDK4 | |
| SCHEMBL24327561 | 0.86 | EGFR (0.72) | EGFRBRD4IGF1RALKJAK2 | |
| SCHEMBL24352065 | 0.85 | EGFR (0.45) | EGFRBRD4INSRIGF1RALK | |
| SCHEMBL27031685 | 0.85 | EGFR (0.45) | EGFRBRD4INSRIGF1RALK | |
| SCHEMBL24351882 | 0.84 | EGFR (0.44) | EGFRBRD4INSRIGF1RALK | |
| SCHEMBL24327079 | 0.84 | ALK (0.54) | EGFRINSRIGF1RALKMET | |
| SCHEMBL29904631 | 0.84 | EGFR (0.64) | EGFRBRD4INSRIGF1RALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| WO-2022063106-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEIGENE, LTD. (KY) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | EGFR 1/4885BRD4 517/4885INSR 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.